Other ASV studies
With our programme to research clinical areas related to sleep-disordered breathing, we aim to further develop our in-depth knowledge on sleep and respiratory disorders. That’s why we support and actively engage in research initiatives.
CAT HF is a multi-centre, randomised and controlled trial aiming to assess the effects of ASV in patients after a hospitalisation for acute decompensated heart failure. It began in multiple US sites in September 2013. Recruitment was stopped prematurely when ResMed issued an Adaptive Servo-Ventilation (ASV) therapy Field Safety Notification. However, the preliminary findings suggest that ASV may be beneficial in HF patients with preserved ejection fraction.1
The FACE study is a French and Belgium prospective, multicentre, observational cohort that will provide long-term data on morbidity and mortality of heart failure (both HFrEF and HFpEF) patients using ASV. So far over 400 patients have been enrolled by 30 centres.
Since May 2015, the recruitment has been limited to patients with HFpEF, with a target of 300 chronic HFpEF patients.
Interim data from the FACE cohort seems to confirm these findings2, and provide some positive insights in HFpEF
- The FACE prospective cohort aimed to provide real-world data about the prognosis of HF patients with CSA treated with ASV. This interim analysis provides some long-term morbidity and mortality data of 391 HF patients (HFrEF, HFmrEF or HFpEF) eligible to ASV therapy followed during 2 years.
- Severe hypoxemia (high T90) during sleep is a strong independent risk factor for mortality in HF patients (HR=12).
- ASV therapy was associated with a better prognosis in CHF patients with severe nocturnal hypoxaemia or non-ischemic etiology, especially in subgroups with middle-range or preserved LVEF but not with reduced LVEF.